Clinical Trials Directory

Trials / Unknown

UnknownNCT05392348

Human Gut Microbiota and microRNA Expression

Regulatory Effect of Stachyose on Gut Microbiota and microRNA Expression in Human

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
36 (estimated)
Sponsor
Xijing Hospital · Academic / Other
Sex
All
Age
18 Years – 30 Years
Healthy volunteers
Accepted

Summary

In this study, stachyose was used as an intervention factor. We will evaluate changes in fecal gut microbiota and miRNA expression profiles in subjects under stachyose intervention

Detailed description

In the stachyose intervention group, each person in the stachyose intervention group took 5 g of stachyose daily before breakfast, and the administration method was 100 ml of drinking water dissolved and taken orally for two months. Each person in the placebo control group took the same amount of maltodextrin daily. Stool samples of the subjects were collected weekly.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTstachyoseStachyose is a tetrasaccharide consisting of sucrose having an alpha-D-galactosyl-(1-\>6)-alpha-D-galactosyl moiety attached at the 6-position of the glucose.
DIETARY_SUPPLEMENTMaltodextrinMaltodextrin is a polysaccharide that is used primarily in foods and beverages as a thickener, sweetener, and/or stabilizer. It is a relatively short-chain polymer (some would call it an oligomer); commercial products contain an average of ≈3 to ≈17 glucose units per chain. It is manufactured by partially hydrolyzing grain starches, usually corn or wheat.

Timeline

Start date
2022-05-25
Primary completion
2022-06-25
Completion
2022-06-30
First posted
2022-05-26
Last updated
2022-05-26

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05392348. Inclusion in this directory is not an endorsement.